Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
GEN Roundup: Multiplex Immunoassays Bring the Array, Not the Disarray
Get Multiplex Immunoassay Advice from GEN's Expert Panel
Solving the Puzzle of Cell Culture Optimization
Assembling a Jigsaw Puzzle Is Not Nearly as Tricky as Building a Stable and Productive Bioprocess
For full access to this article login to GEN Select now.
Seizing Immunoassay Opportunities
Growth Prospects—Flecks of Hidden Gold—Still Occur in an Otherwise Mature Market
- At first glance, the immunoassay market would seem to offer little to healthcare marketers or investors seeking high revenue growth opportunities. Immunoassays are, frankly, an older category of tests. The first tests were launched in the 1960s. Some of the companies of that era still operate, though under different ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.